Haleon, the manufacturer of Sensodyne, has identified a growth target skewed towards the second half of 2025. As a low-priced pharma stock, some are questioning whether it's the best investment, whilst its recent earnings results have places shares under scrutiny. With 2024's adjusted profit increasing while revenue declined, a £500 million allocation for share buybacks in 2025 has been announced. Haleon has met expectations, though some analysts and investors deems this unsatisfactory. Company executives have been acquiring shares under a reward plan, as Pfizer unloads hundreds of millions of Haleon shares, taking its stake to 7.3%. Haleon continues to strengthen its share value, even initiating a buyback program. Other investors including BlackRock are increasing their stake, while major shareholder Pfizer is reducing its stake. Meanwhile, Haleon plans to invest $54 million in a U.S research and development centre to foster product innovation.
Haleon Stocks News Analytics from Thu, 16 May 2024 07:00:00 GMT to Fri, 28 Feb 2025 17:55:28 GMT -
Rating 5
- Innovation 2
- Information 4
- Rumor -2
